Pelthos Therapeutics Inc.(PTHS)
$26.78—
Pelthos Therapeutics Inc.(PTHS)
NYSE
$26.78—
Q4 2026 EPS Estimate
$-2.90
Nov 12, 2026 · Reports before open
Revenue Estimate
$18M
FY2028E EPS$1.53
FY2029E EPS$4.33
Analyst Sentiment
Wall St. Consensus
Buy3 analysts·Low coverage
75
Score
3 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
3100%
Hold
00%
Sell
00%
Strong Sell
00%
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price Target Expectations
Bear
$45.00
+68.0%
Consensus
$54.50
+103.5%
Bull
$64.00
+139.0%
12-Month Target Range3 analysts
$45.00$54.50$64.00
Current $26.78Consensus
Current Price
$26.78
Upside to Consensus
$27.72
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
Earnings & Revenue Estimates
Forward Growth Estimates (YoY)
FY2027
Rev+76.03%
EPS—
FY2028
Rev+41.89%
EPS—
FY2029
Rev+31.83%
EPS+183.18%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $64M | $112M | $159M | $210M | $249M |
| Low | $60M | $105M | $96M | $161M | $191M |
| High | $71M | $129M | $198M | $250M | $297M |
| EBITDA Avg | $38M | $67M | $96M | $126M | $149M |
| Low | $36M | $63M | $58M | $96M | $114M |
| High | $43M | $77M | $119M | $150M | $178M |
| EBIT Avg | $38M | $67M | $96M | $126M | $149M |
| Low | $36M | $63M | $58M | $96M | $114M |
| High | $43M | $77M | $119M | $150M | $178M |
| Net Income Avg | $-29M | $-4M | $4M | $8M | $13M |
| Low | $-33M | $-27M | $-2M | $6M | $9M |
| High | $-26M | $18M | $10M | $10M | $16M |
| EPS Avg | $-16.04 | $-3.90 | $1.53 | $4.33 | $6.72 |
| Low | $-17.41 | $-14.15 | $-1.33 | $3.01 | $4.68 |
| High | $-13.96 | $9.59 | $5.18 | $5.40 | $8.39 |
| Analysts (Rev / EPS) | 6 / 4 | 6 / 5 | 6 / 6 | 4 / 3 | 3 / 2 |
Quarterly
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $18M | $19M | $21M | $27M | $31M | $30M |
| Low | $16M | $17M | $17M | $23M | $26M | $25M |
| High | $20M | $24M | $25M | $32M | $38M | $37M |
| EBITDA Avg | $11M | $12M | $12M | $16M | $19M | $18M |
| Low | $10M | $10M | $10M | $14M | $16M | $15M |
| High | $12M | $14M | $15M | $19M | $23M | $22M |
| EBIT Avg | $11M | $12M | $12M | $16M | $19M | $18M |
| Low | $10M | $10M | $10M | $14M | $16M | $15M |
| High | $12M | $14M | $15M | $19M | $23M | $22M |
| Net Income Avg | $-10M | $-10M | $-4M | $-2M | $-212,367 | $-707,893 |
| Low | $-17M | $-18M | $-5M | $-2M | $-269,928 | $-899,767 |
| High | $-6M | $-4M | $-3M | $-1M | $-167,945 | $-559,801 |
| EPS Avg | $-2.90 | $-2.69 | $-1.13 | $-0.53 | $-0.06 | $-0.20 |
| Low | $-4.72 | $-4.99 | $-1.44 | $-0.67 | $-0.08 | $-0.25 |
| High | $-1.64 | $-1.17 | $-0.90 | $-0.42 | $-0.05 | $-0.16 |
| Analysts (Rev / EPS) | 5 / 4 | 5 / 4 | 4 / 1 | 4 / 1 | 4 / 1 | 4 / 1 |